Thursday, May 24, 2018
engineered enzymes for better healthcare

Pipeline

Enzolve Technologies has now successfully launched its Phenylketonuria (PKU) screening test (April 2009). This has completed the CE marking approval process and is the first in the NeoScreenPak series to which two additional tests, one for galactosaemia (Total Galactose) and another for glucose-6P dehydrogenase deficiency (G6PD), will be added soon.


Technology Advantages Pipeline


Language Selection

Search

Latest News

Newborn Screening - First Steps into the marketplace
Irish technology to enable metabolic disorder screening among newborns in the developing world and remote locations... Read full article on the web Technology…

Read more...

Screen your baby’s health
Enzolve Technologies recently launched a novel newborn screening test for Phenylketonuria (PKU), an inherited metabolic disorder that results in severe mental…

Read more...

UCD campus company to begin production of newborn screening kits for international markets
Enzolve Technologies has recently secured substantial investment from Enterprise Ireland to allow them to begin immediate production of diagnostic screening kits…

Read more...